News

Glyxambi is approved as an adjunct to diet and exercise to improve glycemic control in these adults when both empagliflozin and linagliptin are appropriate treatments. The drug is

Factor VIIa-CTP is a new, long-acting recombinant Factor VIIa using the company’s proprietary technology to extend its circulatory half-life without the use of polymers, encapsulation techniques or nanoparticles.

As of this date, Amherst has not paid or entered into an agreement to pay the FDA the amount owed. Under the terms of our agreement with Amherst,

"Through the acquisition of Aquarius and its novel lipid-based, targeted drug delivery platform, Matinas BioPharma significantly expands its technological portfolio with several product candidates in the field of

The therapeutic focus will be on acute bleeding in the lungs (Diffuse Alveolar Hemorrhage) and if successful Serendex Pharmaceuticals might be able to offer breakthrough therapy in this

"Executing on VTI-208 has been our primary focus over the last two years at about 50 leading hospitals in the U.S., Europe and Australia," said Terry Winters, Ph.D.,

The primary endpoint of the GIFT-I study was achieved, demonstrating a 95 percent (n=106/112) sustained virologic response rate at 12 weeks post treatment (SVR12) in the sub-group of

Zohydro ER is developed to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BeadTek is designed to

Compared to other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatory drugs, Anatabine Citrate has a distinct anti-inflammatory mode of action. The three-part Phase I trial